Welcome to our dedicated page for Cyclacel Phar Pr news (Ticker: CYCCP), a resource for investors and traders seeking the latest updates and insights on Cyclacel Phar Pr stock.
The CYCCP news page on Stock Titan tracks disclosures and press releases related to Cyclacel Pharmaceuticals, Inc.’s 6% Convertible Exchangeable Preferred Stock and the broader corporate developments of the issuer. Company communications describe Cyclacel as a clinical-stage biopharmaceutical company developing cancer medicines based on cell cycle, epigenetics, transcriptional regulation and mitosis biology, with a key focus on the PLK1 inhibitor plogosertib in solid tumors and hematological malignancies.
News items for CYCCP include quarterly financial results, where Cyclacel reports cash resources, research and development spending, and general and administrative expenses, together with commentary on cost reductions, changes in research focus and going concern considerations. These updates often describe the impact of the liquidation of the UK subsidiary Cyclacel Limited, the deconsolidation of that entity’s results, and the company’s decision to concentrate resources on the plogosertib program.
Investors will also find scientific and clinical updates, such as press releases highlighting independent preclinical publications on plogosertib in biliary tract cancer and fibrolamellar hepatocellular carcinoma. These items summarize how PLK1 inhibition and potential biomarkers like BUBR1 or DNAJ–PKAc fusion status may relate to sensitivity to plogosertib, and they provide context for the company’s translational biology strategy.
Another category of CYCCP-linked news covers corporate and capital markets actions, including private placements of Series F Convertible Preferred Stock and associated warrants, amendments to preferred stock and warrant terms, reverse stock splits, and Nasdaq compliance updates. Press releases also detail the Exchange Agreement with FITTERS Diversified Berhad to acquire Fitters Sdn. Bhd., a Malaysian fire safety and protective equipment business, and describe shareholder approvals for share issuances and a corporate name change to Bio Green Med Solution, Inc.
By reviewing this news feed, holders and prospective investors in CYCCP can follow how Cyclacel’s oncology development activities, strategic transactions, financing steps and corporate rebranding are described in its own public statements and SEC-related communications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) announced its participation in two upcoming investor conferences. The Oppenheimer 33rd Annual Healthcare Conference will be held virtually from March 13-15, 2023, featuring a fireside chat on March 13 at 10:00 am ET led by Spiro Rombotis. The 35th Annual Roth Conference takes place in Dana Point, CA from March 12-14, 2023, with a fireside chat on March 13 at 3:00 pm PT presented by Paul McBarron. Cyclacel is focused on developing innovative cancer treatments targeting cell cycle and transcriptional regulation.
Cyclacel Pharmaceuticals reported its 2022 financial results and outlined key objectives for 2023. The company aims to advance oral fadraciclib into Phase 2 trials and explore the potential of oral plogosertib. They anticipate multiple data readouts including interim results from their Phase 1/2 studies. As of December 31, 2022, cash and equivalents were $18.3 million, down from $36.6 million in 2021, with a net loss of $21.2 million. R&D expenses rose due to ongoing trials for both drug candidates. The company believes it can fund operations through the fourth quarter of 2023.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) is set to announce its fourth quarter and full year 2022 financial results on March 6, 2023, at 4:30 PM ET. Following the announcement, a conference call will be hosted to discuss the results and company updates. Investors can access the call via toll-free numbers or webcasts. Cyclacel focuses on developing innovative cancer therapies, including the CDK2/9 inhibitor fadraciclib and the PLK1 inhibitor plogosertib. The company’s strategy aims to establish a diversified pipeline addressing oncology and hematology indications.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) will present an overview of its business and clinical programs at the BIO CEO & Investor Conference on February 6-9, 2023. CEO Spiro Rombotis is scheduled to speak on February 6 at 9:30 AM ET in the Music Box room at the New York Marriott Marquis Times Square. The Company, focused on developing innovative cancer treatments, is available for meetings with attendees through the BIO One-on-One Partnering system. Cyclacel is advancing multiple drug candidates, including fadraciclib and plogosertib, targeting oncology and hematology indications. For more information, visit cyclacel.com.
Cyclacel Pharmaceuticals (CYCC, CYCCP) has made significant strides in 2022, focusing on its two leading drug candidates, fadraciclib and plogosertib, which are in Phase 1/2 clinical studies. The company anticipates starting Phase 2 trials for fadraciclib in 1Q 2023, following promising early results including 2/3 partial responses in T-cell lymphoma. With sufficient cash reserves projected to last through 2023, Cyclacel expects key data readouts this year, providing further insight into both drugs' efficacy and safety.
Cyclacel Pharmaceuticals plans to present at the Biotech Showcase and host meetings at a Corporate Access Event from January 9-11, 2023, in San Francisco. Spiro Rombotis, CEO, and Paul McBarron, EVP, will discuss the company's clinical advancements and goals. The Biotech Showcase presentation is on January 10 at 9:30 am PT at Hilton San Francisco Union Square. Cyclacel focuses on cancer therapies, particularly fadraciclib and CYC140, addressing solid tumors and hematological malignancies. For more details, visit www.cyclacel.com.
FAQ
What is the current stock price of Cyclacel Phar Pr (CYCCP)?
What is the market cap of Cyclacel Phar Pr (CYCCP)?
